Hepatocellular Carcinoma-Targeted Icariside II Nanomicelles: Engineering a Glycyrrhetinic Acid-Modified Copolymer Platform for Enhanced Tumor Therapy
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Zheng Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of…. Hauptthemen laut MEDLINE: Glycyrrhetinic Acid, Carcinoma, Hepatocellular, Liver Neoplasms, Polymers. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Department of Science and Technology of Shandong Province, Graduate Innovation Foundation of Yantai University.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is one of the leading causes of death worldwide, accounting for about 90% of all primary liver malignancies. The emergence of natural antitumor compounds provides a new strategy for the treatment of HCC, but their delivery in vivo has become a major problem. In this study, the copolymer of the natural product glycyrrhetinic acid (AMGA) was prepared and served as a carrier for encapsulation of the natural active ingredient Icariside II (AMGA@ICAII). The results show that AMGA still retains the interaction with GA-R and achieves active targeting by interacting with GA-R. In addition, GA-modification changes the physical chemistry nature of the carrier, providing it with better colloidal stability. AMGA@ICAII significantly inhibited the proliferation of the human hepatoma cell line HepG-2 in vitro compared with other treatment groups. Furthermore, AMGA@ICAII improved the distribution of ICAII in the C57BL/6J mouse Hepa1-6 hepatoma model and showed a significant antitumor effect. This work demonstrated that small molecule target modification in the hydrophobic segment of block copolymer will do benefit to improve the performance of the carrier, while retaining ligand-receptor-mediated targeting properties and providing a reference for the targeted delivery of anticancer agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Minis…
- Yantai Dongcheng Pharmaceutical Group Co., Ltd., Yantai 264006, China.
- School of Food and Biological Engineering, Yantai Institute of Technology, Yantai 264003, China.
- School of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, China.
Förderung
- Department of Science and Technology of Shandong Province
- Graduate Innovation Foundation of Yantai University
Zitieren
APA
Sun, Z., Li, Z., Hao, T., Liu, X., Jiang, Y., Ping, S., Dong, N., Guo, R., Yang, X., & Xu, H. (2025). Hepatocellular Carcinoma-Targeted Icariside II Nanomicelles: Engineering a Glycyrrhetinic Acid-Modified Copolymer Platform for Enhanced Tumor Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00461
Vancouver
Sun Z, Li Z, Hao T, Liu X, Jiang Y, Ping S, et al. Hepatocellular Carcinoma-Targeted Icariside II Nanomicelles: Engineering a Glycyrrhetinic Acid-Modified Copolymer Platform for Enhanced Tumor Therapy. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00461
BibTeX
@article{Sun2025,
author = {Sun, Zheng and Li, Zhiyong and Hao, Teng and Liu, Xuecun and Jiang, Yuanyuan and Ping, Songyuge and Dong, Na and Guo, Ruiling and Yang, Xin and Xu, Hui},
title = {Hepatocellular Carcinoma-Targeted Icariside II Nanomicelles: Engineering a Glycyrrhetinic Acid-Modified Copolymer Platform for Enhanced Tumor Therapy},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00461}
}
EUVIMED